Evotec AG announced that it has appointed Dr. Werner Lanthaler as its Chief Executive Officer, effective immediately. Previously, Dr. Lanthaler was Chief Financial Officer of Intercell AG in Vienna, Austria, a global biopharmaceutical leader focused on developing vaccines. In his position as CFO, he was also responsible for Business Development and Marketing & Sales.

During his eight-year tenure at Intercell, the biopharmaceutical company evolved from a venture-backed biotechnology company into a global vaccine player. Dr. Lanthaler played a key role in many of the company’s major corporate milestones including the most recent product approval of Intercell’s Japanese Encephalitis Vaccine, the company’s acquisitions and strategic pharma partnerships, as well as the company’s Initial Public Offering on the Vienna Stock Exchange in 2005.

Dr. Flemming Ornskov, Chairman of the Supervisory Board of Evotec, commented, “Dr. Lanthaler is an ideal candidate to be CEO of Evotec at this juncture. His experience in building a highly successful company, his impressive track record in business and corporate development, and his strong sense for the creation of shareholder value are a perfect match with Evotec’s strategy to transform itself into a streamlined biopharmaceutical company. In summary, he brings all the skills and experience needed in order to adapt and shape Evotec’s strategy and move the Company to the next level of success.”

“I look forward to joining this exciting company in a challenging market environment. It possesses an abundance of opportunities based on good fundamental science, an excellent reputation for drug discovery and development, and strong financial resources. It is my goal to advance Evotec’s vision and generate significant shareholder value in the years to come,” stated Dr. Werner Lanthaler, the Chief Executive Officer of Evotec.